TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

About this update from Tg Therapeutics, Inc.

[{"type":"image","alt":"TG Therapeutics, Inc.","displaySize":"","headline":null,"caption":"TG Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/cc1df9bb4678bf5c14f62e021fa1fad1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kJRuP1U4UFEdpu7yaRZIrA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc1df9bb4678bf5c14f62e021fa1fad1","width":300,"height":79}},"lazy":false},{"type":"text","content":"NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 5 – 7, 2026 in San Diego, California. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the upcoming presentations are outlined below.","length":526,"tagName":"p"},{"type":"text","content":"TG PRESENTATIONS:Poster Presentation Title: Real-World Infusion Experience with Ublituximab in ENABLE: the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating Ublituximab","length":211,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Presentation Date/Time: Friday, Feb. 6, 2026, 6:45 – 7:30pm PST","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"Session: Poster Session 2","length":25,"tagName":"p"}]},{"val":[{"type":"text","content":"Abstract Number/Poster Number: 387/P413","length":39,"tagName":"p"}]},{"val":[{"type":"text","content":"Lead Author: Carrie Hersh, DO, MSc, FAAN - Cleveland Clinic Lou Ruvo Center for Brain Health (CCLRCBH) (MS) & Neuroimmunology Specialist – Assoc. Professor of Neurology at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University","length":254,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":381,"olType":false},{"type":"text","content":"Poster Presentation Title: Study Design of a Phase 2 Ublituximab Dose Confirmation Study in Children and Adolescents with Relapsing Multiple Sclerosis: ULTIMATE KIDS I","length":167,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Pres...

More updates from Tg Therapeutics, Inc.